Detalhe da pesquisa
1.
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 383(13): 1218-1230, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945632
2.
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
Future Oncol
; 18(19): 2361-2371, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35416053
3.
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
Urol Oncol
; 41(12): 461-475, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37968169
4.
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
JAMA Oncol
; 9(1): 29-39, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394867
5.
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Diagn Pathol
; 11(1): 95, 2016 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717372
6.
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
J Clin Oncol
; 34(26): 3119-25, 2016 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27269937
7.
Thrombotic microangiopathy with targeted cancer agents.
Clin Cancer Res
; 17(18): 5858-66, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21813634